ACE2 Inhibitors Block Coronavirus Spike Protein Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, such as SARS, MERS, and COVID-19, lack effective methods to inhibit viral entry and replication, particularly in utilizing ACE2 inhibitors to block the binding of viral spike proteins to host cells.
Innovation Solution
Administering therapeutically effective amounts of ACE2 inhibitors like MLN-4760, DX600, ORE-1001, Equivir, and Landefill, or their pharmaceutically acceptable salts, to prevent or treat coronavirus infections by obstructing viral binding, reducing viral load, and minimizing downstream effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACE2 inhibitors are administered to block viral entry, then viral transmission and replication are inhibited, but the mechanism of action requires specific binding to ACE2 receptor which limits broad-spectrum applicability
Solution Approach 1:
The patent uses ACE2 inhibitors as intermediary compounds that mediate between the viral spike protein and the ACE2 receptor. These inhibitors act as molecular mediators that bind to ACE2 with high affinity, preventing direct viral-receptor interaction while maintaining the natural binding interface, thereby providing reliable blockage of viral entry.
Solution Approach 2:
The patent employs multiple ACE2 inhibitor compounds with varying chemical structures and binding parameters (MLN-4760, DX600, ORE-1001, Equivir, and Landefill). By changing the chemical parameters of the inhibitors, the patent optimizes binding affinity and selectivity for ACE2, improving reliability of viral entry blockage while the diverse chemical space provides some adaptability to different coronavirus strains.
2Reliability
If ACE2 inhibitors are used to treat coronavirus infections, then therapeutic benefits are achieved by obstructing viral binding, but the complexity of identifying and developing effective ACE2 inhibitors increases
Solution Approach 1:
The patent performs preliminary identification and characterization of multiple ACE2 inhibitor compounds (MLN-4760, DX600, ORE-1001, Equivir, and Landefill) with demonstrated efficacy against coronaviruses. By conducting preliminary screening and validation of these compounds, the patent reduces the complexity of future drug development by providing a pre-validated list of effective inhibitors that can be directly applied to treat SARS, MERS, and COVID-19.
Solution Approach 2:
The patent identifies ACE2 inhibitors that serve multiple functions: they block viral entry by competing with spike proteins for ACE2 binding, reduce viral load by preventing infection, and can be applied across different coronavirus types (SARS-CoV, MERS-CoV, SARS-CoV-2). This multi-functionality reduces development complexity by using a single class of compounds for multiple therapeutic indications.
3Reliability
If ACE2 inhibitors obstruct viral binding to ACE2 receptor, then viral cell entry is prevented, but the specificity to ACE2 receptor binding mechanism limits treatment options
Solution Approach 1:
The patent employs a composite approach by combining multiple ACE2 inhibitor compounds with different chemical structures (peptide-based, small molecule-based) that all target the ACE2 receptor. This composite strategy provides reliable blockage through multiple molecular mechanisms while offering treatment flexibility by selecting from different compound classes based on specific infection scenarios and patient needs.
Data Source
AI summary
The present invention is directed to, in part, methods of preventing and/or treating coronavirus infection. In some embodiments, provided herein are methods of preventing or treating an infectious disease caused by coronavirus (e.g., SARS, MERS, and COVID-19) comprising administering to a subject in need thereof a compound described herein (e.g., MLN-4760, DX600, ORE-1001, Equivir, Landefill, and other ACE2 inhibitors).